Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices trim early losses as Iran supply fears overshadow Russia measures Hormuz oil flows down 97% from normal levels, Goldman Sachs says Gold prices rise but head for second weekly loss as Iran war spurs inflation fears Wall Street ends deep in the red amid renewed spike in oil prices due to Iran war (South Africa Philippines Nigeria) Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot By Analyst Ratings Published 03/13/2026, 05:15 AM Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot 0 KRRO -2.21% Investing.com - Raymond James upgraded Korro Bio Inc. (NASDAQ:KRRO) from Market Perform to Outperform with a price target of $23.00. The upgrade is driven by an improved outlook for the company’s pivot into hyperammonemia indications urea cycle disorders and hepatic encephalopathy. Korro Bio presented preclinical data at a recent Virtual Analyst Day supporting the path forward in these indications. The data, combined with a recent $85 million oversubscribed PIPE, extends the company’s cash runway to the second half of 2028. According to InvestingPro data, the company holds more cash than debt on its balance sheet, with a current ratio of 6.9, though it is quickly burning through cash—insights reflected in two of the 10+ exclusive ProTips available to subscribers. Raymond James said this gives line of sight for Korro Bio to get through proof-of-concept and potentially through a pivotal program in one or more indications with very high unmet need and no approved therapies. Korro Bio expects to file an IND for KRRO-121 in the second half of 2026. The company also plans to nominate development candidates for its GalNAc-based AATD program in the second quarter of 2026. A third GalNAc-conjugated program is planned for nomination in the second half of 2026.The stock, currently trading at $11.50 with a market cap of $114 million, has shown significant volatility—down 62.61% over si...
Read full article at source